Drug Discovery - Research & Development

Sandoz, Just – Evotec Biologics tie up to develop multiple biosimilars

Sandoz and Evotec’s Seattle-based subsidiary, Just - Evotec Biologics have reached a multi-year, long-term tech alliance to develop and manufacture multiple biosimilars.

Life Bio, Forge to develop gene therapies for aging-linked diseases

Life Biosciences has announced a cGMP manufacturing collaboration with Forge Biologics for advancing the development of new gene therapies to treat aging-related diseases.

Neogap, Cellerys partner for study of multiple sclerosis therapy

Biopharmaceutical company Neogap Therapeutics has partnered with Swiss company Cellerys for a Phase II study of the latter’s RED4MS therapy for multiple sclerosis.

Stablix, Vertex partner to develop targeted protein stabilisation therapies

Biopharmaceutical company Stablix and Vertex Pharmaceuticals have joined forces to discover and develop targeted protein stabilisation (TPS) therapies.

Boehringer Ingelheim opens new biotechnology R&D centre in Germany

Boehringer Ingelheim has opened its new advanced Biologicals Development Center (BDC) in Biberach an der Riß, Germany.

Talem, Xyphos sign agreement for potential cancer therapeutic candidates

ImmunoPrecise Antibodies (IPA) subsidiary, Talem Therapeutics has entered into a research collaboration and licence option agreement with Astellas Pharma’s wholly-owned subsidiary, Xyphos Biosciences.

Macomics signs collaboration deal with Ono Pharmaceutical

Macomics and Ono Pharmaceutical have entered into a global collaboration deal for the discovery and development of macrophage-targeting antibody therapy for cancer.

Dewpoint, Novo Nordisk to identify drug candidates for diabetic complications

Dewpoint Therapeutics has formed a research and development partnership with Novo Nordisk for identifying drug candidates to treat insulin resistance and diabetic complications.

Tempus, Pfizer partner for cancer drug development

Tempus has unveiled a multi-year strategic partnership with Pfizer for advancing the development of cancer drugs.